Lung Cancer Market Size, Share, By Type (Small cell lung cancer (SCLC), Non-small cell lung cancer (NSCLC)), By Treatment (Chemotherapy, Laser Therapy, Radiotherapy, Immunotherapy, Surgery, and Others), By End-Users (Hospitals, Clinics, Cancer Research Centers, Laboratories, and Others) and Region - Trends, Analysis and Forecast till 2034

Lung Cancer Market Size was valued at USD 35.2 Billion in 2024 and is expected to reach USD 164.7 Billion by 2034, growing at a CAGR of 18.5%

When cancer starts in lungs is called as Lung Cancer. Cancer begins in lungs and spread into lymph nodes and other organs like brain. In metastases cancer is spread from one organ to another. Tobacco, cigarette smoking are main causes of lung cancer. Chest pain, wheezing, coughing, weight loss, feeling tired, shortness of breath are some symptoms of lung cancer. Individual with lung cancer experience shortness of breath in which cancer grows by blocking airways, fluid accumulate around the lungs, coughing with blood, etc. Loss of appetite, shortness of breath, chest pain, coughing up blood, weakness, weight loss are first signs of lung cancer. Five years survival rate for non-small cell lung cancer is 26%, five years survival rate for all types of lung cancer in people is 22%. Individual who smokes cigarette are 15-30 times more at risk to get lung cancer or die due to lung cancer. Lung cancer has become the leading cause of death by cancer, which has made almost 25% of all cancer deaths. Lung cancer spreads rapidly due to its aggressiveness. Early diagnosis and treatment help in improving chances of living for people with lung cancer for more than five years. Mostly lung cancer spreads or metastasizes in brain, liver, adrenal glands or bones. Lung cancer stars in bronchioles, alveoli, and cell lining bronchi. Lung cancer causes pain and discomfort when tumor starts growing larger. Stage I lung cancer can be curable if treated early by radiation therapy or chemotherapy. Fully cure lung cancer is difficult in patients having more advanced tumor. Lung cancer is removed by lobectomy and bilobectomy. In bilobectomy two lobes are removed. Lung cancer is treated by targeted therapy, radiation therapy, chemotherapy, and by surgery. Individual with SCLC (small lung cancer) are treated with chemotherapy and radiation therapy. Adenocarcinomas has 261 days of median doubling time, small cell carcinomas and large cell carcinomas has 70 days of median doubling time, and squamous cell carcinomas has 70 days of median doubling time. Rise in cigarette smoking, incidence of cancer diseases has enhanced the growth of lung cancer market.

Key Drivers of Target Market:

The Demographic Time Bomb

• The current world is more aging every day, and unfortunately, the risk of developing lung cancer increases with age. This creates a perfect storm where a rising patient pool seeks diagnosis, treatment, and supportive care. This rise in demand propels the markets of diagnostic tools, therapeutic modalities, and supportive care services.
• A Beacon of Hope, A multitude of arms and ammunition continue to be added to this battlefield against lung cancer. Minimally invasive surgical techniques such as video-assisted thoracoscopic surgery reduce recovery times and decrease surgical trauma. Sophisticated imaging modalities, like PET scans, provide exquisite details of anatomy and function and help in accurate diagnosis and planning of treatment. Precision medicine approaches—targeted and immunotherapies—involve actions at a much more personal level, presenting a laser focus on the cancer cells themselves while causing minimal damage to healthy tissue. These move the market growth forward as better patient outcomes are achieved.

Rising Awareness: Paradigm Shift

• Increased awareness toward the risk factors of lung cancer due to smoking and environmental pollution is now reflecting in a paradigm shift. It places power in the hands of individuals to make a choice from a position of knowledge in matters that pertain to the diseases and may lead towards early diagnosis. Early detection is key because it dramatically improves the prognosis and success of treatment. In addition, there are advocacy groups that have been taking on the task of sensitizing the masses and have increasingly been putting pressure on the government to finance the research on lung cancer. That creates more fertile ground for market innovation.
• Early Detection: Steal the Show in a Race Against Time pNext-generation low-dose CT scans, as an effective screening tool, are opening a huge potential market. As early detection offers corrective measures and curative treatments before the disease progresses to an endemic stage, greater chances of survival are seen on the side of the patient. Such emphasis on early detection drives demand for effective screening tools and minimally invasive diagnostic procedures.

Restrains:

High Cost Implementation

• The cost of advanced diagnostics and innovative treatments is many times very high and thus creates a high barrier for patients and health systems. This is pronounced in developing economies, where resource constraints doom access to such life-saving interventions. This directly translates to the fact that the high cost of treatment can suffocate market growth in these regions, hence requiring effective solutions and better models of financing healthcare.
• Treatment is considerably improved, but it is of limited efficacy, and some subtypes are more resistant to therapy. Present therapies may not prove curative in all cases, and some cancers become resistant after a few years. This clearly indicates the necessity for continuous research and development in order to find out new targets and new therapy strategies. The market is ripe for any breakthrough discovery that can yield man the ultimate or final cure for lung cancer.

A Global Challenge in Healthcare Disparities

• Tremendously unequal access to high-quality healthcare may lead to a vast inequality in the outcomes from lung cancer. Patients in these geographies may not have timely access to diagnosis, specialized treatments, or adequate supportive care. This bodes not only for the well-being of the patients but also for the overall underpenetrated lung cancer market. The plan to reduce health disparities involves infrastructure development, improvement in the trainings of healthcare workers, and global collaboration.
• Ensuring safety but expediting access, the long drawn-out processes of regulatory approval for new diagnostics and therapies result in delayed entry of innovations to the market, restraining access for patients. It is important to balance ensuring patient safety and speeding up access to potentially life-saving treatment. The way forward may be found in exploring creative ways of accelerated approvals within rigorously set boundaries for safety.

Opportunities:

Personalized Treatments for the Individual

• Genomic profiling, in conjunction with the identification of specific biomarkers that are correlated with lung cancer subtypes, opens up the road to individualized treatment regimens. One can therefore design more focused therapies that are aimed at attacking the vulnerabilities specific to a patient's basic cancer type to maximize efficacy and minimize side effects. Personalized medicine embodies great market potential and a sea change in the management of cancers.

Digital Health Integration

• Empowerment of Patients and Providers: Telemedicine, remote patient monitoring, and AI-powered diagnostics would empower lung cancer management in a big way. Telenursing consultations improve access to care with advantages in remote geographical locations. One would be able to identify treatment-related complications early on by continuous evaluation of the patient's process. Such complex medical data could be analyzed by artificial intelligence to support the diagnosis and treatment plan of drug discovery. These digital health tools empower both the patients and providers in an approach toward patient-centered care delivery.

The market is segmented based on Type, Treatment, End-User, and Region.

Type Insights:

• Small Cell Lung Cancer: This is quite rare compared to NSCLC, comprising only about 15% of the lung cancer cases. Unlike in NSCLC, SCLC usually presents at a more advanced stage of the disease and has a different treatment approach. This kind of aggressive cancer will usually require both chemotherapy and radiotherapy. Surgery is involved less often because this type of cancer tends to be more advanced at diagnosis.
• Non-small Cell Lung Cancer “NSCLC” presents about 85% of all cases of lung cancer. It has multiple subtypes: adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Each subtype may have its own treatment protocols and different considerations within the market. For example, adenocarcinomas are usually associated with specific driver mutations, often amenable to medications targeting these drivers, while squamous cell carcinomas are strongly related to smoking and perhaps are more sensitive to classic therapies such as surgery or radiotherapy.

Treatment Insights:

• Chemotherapy: This is a standardized treatment that involves the use of strong drugs in killing the cancerous cells in the body. The section encompasses various types of chemotherapeutic agents, modes of administration, and constant research on increasing their efficacy and minimizing their side effects. The specific prescription of chemotherapy drugs would depend on the type and stage of the lung cancer setting, apart from other health parameters of the patient.
• Laser Therapy: This is not as common; it does provide selective means of destroying tumors in very specialized situations. This sector is thus a potential niche area of growth, particularly in symptom palliation from obstructing tumors in the trachea or bronchi.
• Radiotherapy: This involves using a certain amount of targeted radiation to kill cancer cells or reduce the size of tumors. The various radiation technologies included in the lung cancer radiotherapy market are External beam radiotherapy - This introduces high-energy rays into the body from a machine, whereas Stereotactic Body Radiotherapy can deliver the precise dose of radiation in a single or few sessions. The kind of radiotherapy applied will depend on the site, size of the tumor, and the condition of the patient.
• Immunotherapy: This is an area where research is going at a fast pace. It is one such form of treatment where the body's immune system is harnessed to recognize these cancer cells and fight them. This segment is of notable growth due to the development of immune checkpoint inhibitors and other immunotherapeutic agents that are capable of acting on certain parts of the immune system to enable it to recognize and kill the cancer cells.  In patients with advanced NSCLC, this new therapy opens new, fledgling hopes, and research is underway in its application at earlier stages of disease and possibly for SCLC.
• Surgery: Surgical procedures are of major significance in the treatment of lung cancer. It especially works well in NSCLC when the cancer is localized and has not spread to other parts of the body. Incorporated in this market are minimally invasive techniques, such as video-assisted thoracoscopic surgery that requires small incisions with cameras to access the site of the operation, and traditional open thoracotomy procedures where it requires a larger incision between the ribs. The type of surgery will be dictated by the size and location of the lung cancer, its stage, and the patient's overall health and lung function.
• Other treatments: This would include new modes of therapy, such as gene therapy, which is likely to help in base genetic mutations driving the growth of cancer cells, targeted therapies against some NSCLC-driving mutations, and the use of supportive care products that alleviate adverse side effects from treatments, improve adherence, and enhance the quality of life in patients. These emerging treatments and supportive care products make up for a growing share of the lung cancer market, with researchers and clinicians chasing after better patient outcomes and improved quality of life.

End-User Insights:

• Hospitals form the largest market segment and are, quite literally, one-stop shops for lung cancer treatment. Other than that, they are integrated with many kinds of equipment and technologies that facilitate diagnosis and treatment processes, such as sophisticated imaging machines, including CT and PET machines, and surgical suites for lung cancer resection, among other radiation therapy equipment, including linear accelerators. Especially, hospitals maintain dedicated oncology departments composed of medical oncologists, radiation oncologists, and thoracic surgeons—all united in opinion for the purpose of treating patients on a personalized basis. This creates demand for a wide array of products and services, from pharmaceuticals and surgical instruments through to radiation oncology software and specially designed beds for post-surgical recovery.
• Clinics: This includes specialized oncology clinics, pulmonology clinics, and even primary care physician offices. These oncology clinics may offer an initial consultation, diagnosis through biopsies, and some other investigative modalities, and finally, some treatment modalities. Chemotherapy, targeted therapies, etc. are some of the options they may conduct based on set-up and expertise available. In such clinics, pulmonologists usually take care of patients with lung cancer, which requires long-term care and also undertakes the management of respiratory symptoms related to the disease or the sequelae of its treatment. Primary care physicians play an initial role in early detection primarily through screening programs and can also judge patients at the early stage for referral purpose to specialists for further diagnosis and treatment.  Products in this category will, thus include diagnostic tools to be used within the outpatient, as well as medications to be administered when visiting the clinic or prescribed and administered at home.
• Cancer Research Centers: They are, in essence research-emphasis centers on the forefront in carrying out the war against lung cancer. They study risk factors and causes of lung cancer, develop new diagnostic tools for earlier and more accurate detection of lung cancer, studies new opportunities of treatment, such as gene therapy and personalized medicine, improving the therapy available and reducing the side effect of treatments. Cancer research centers require special equipment and technologies for conducting scientific research. This, therefore, results in the unique market segment for high-through sequencing machines, genetic analysis, 3D bioprinting technologies for tumor modeling, and high-performance computing systems that analyze data in lung cancer research.
• Laboratories: Tumor diagnosis laboratories, which take much time, have an important place in diagnosing lung cancer through different samples. It is equipped by special equipment in different areas, such as all the pathology labs put the tissue samples under a microscope to look for cancerous cells to establish the type of cancer in the lungs. The cytology labs identify the abnormal cells from fluid samples, such as sputum. The molecular diagnostics labs perform advanced tests to identify abnormal mutations in the lung cancerous cells, which would inform the treatment alternative of targeted therapy. This category is a prime market for diagnostic kits, laboratory equipment like microscopes and cytometers, and molecular analysis tools.
• Others: This is a broader category of all those involved in the provision of care for patients suffering from lung cancer. Home care providers offer support services for lung cancer patients recuperating at home, including administering medication, managing pain, and providing emotional support. Ambulance services are important in transporting patients to and from hospitals, either for diagnosis or treatment, and at times of emergencies. Public health agencies implement lung cancer screening programs for its early detection and spread awareness about it. They can provide, in partnership with various entities, access to such screening as well as educational activities emanating from them.

Regional Insights

• North America has always captured the maximum market share for lung cancer. The factors attributed to this are: High prevalence rate of lung cancer because of historic, as well as present, tobacco intake; Well-developed infrastructural facilities in the healthcare sector paired with availability of sophisticated diagnosis and treatment facilities; Proactive research and development in new lung cancer treatments; Relatively high per capita healthcare expenditure.
• Europe: It will be a huge market for the treatment of lung cancer in Europe due to the large patient population, aging demographics, developed healthcare systems with established structures for reimbursement, and increasing adoption of advanced treatment options such as targeted therapies and immunotherapies. There is also an increase in government funding toward cancer research.
• Asia Pacific: This region is likely to develop as the fastest-growing market of lung cancer due to the following factors: The rapidly growing and aging population increases the number of potential cases of lung cancer. Growing awareness about lung cancer, resulting in increased screening programs. Economic growth and increasing expenditure on healthcare. Better access to higher-end treatment options; however, inequities prevail across regions.
• Latin America: Much like other developing regions, such as the Middle East and Africa, Latin America has its share of problems in the lung cancer market: Access to advanced diagnostics and treatment is really poor in some countries. The spending on health is lower compared to North America and Europe. However, the interest in building up infrastructure concerned with cancer care and access to therapy is gathering momentum in this region.
• Middle East and Africa: The major challenges that the lung cancer market has to face in this region are as follows: Access to the latest diagnostic and treatment facilities is not available in all parts of this region. Per capita expenditure on healthcare is considerably less than that in developed regions. More investment in infrastructure and training of health professionals is called for. Initiations are being taken to make access to lung cancer care easier and create greater awareness in this region.

Lung Cancer Market Report Scope:

Attribute	Details
Market Size 2024	US$ 35.2 Billion
Projected Market Size 2034	US$ 164.7 Billion
CAGR Growth Rate	18.5%
Base year for estimation	2023
Forecast period	2024 – 2034
Market representation	Revenue in USD Billion & CAGR from 2024 to 2034
Market Segmentation	By Type - Small cell lung cancer (SCLC), Non-small cell lung cancer (NSCLC) By Treatment - Chemotherapy, Laser Therapy, Radiotherapy, Immunotherapy, Surgery, and others By End-Users - Hospitals, Clinics, Cancer Research Centers, Laboratories, and others
Regional scope	North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2024 to 2034. For the purpose of this study segmented the target market report based on type, treatment, end-users, and Region.

By Type:

• Small cell lung cancer (SCLC)
• Non-small cell lung cancer (NSCLC)

By Treatment:

• Chemotherapy
• Laser Therapy
• Radiotherapy
• Immunotherapy
• Surgery
• Others

By End-User:

• Utilities
• Commercial
• Industrial
• Residential

By Region:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • Israel
  • South Africa
  • Rest of Middle East & Africa

The key players operating the Lung Cancer Market include AstraZeneca, Hoffman La Roche, Eli Lilly and Company, Pfizer Inc., Merck & Co., Amgen Inc., Novartis AG, Johnson & Johnson, Teva Pharmaceuticals Industries Ltd., Bristol-Myers Squibb Company

• In June 2022, Novartis has received European Commission approval for ‘Tabrecta’ for treating METex14 skipping advanced NSCLC (non-small cell lung cancer). Newly launched ‘Tabrecta’ has provided new targeted therapy option for patients in Europe with advanced non-small cell lung cancer (NSCLC) which harbor alterations leading to MET exon 14 (METex14) skipping. Tabrecta has become monotherapy for treating adults with advanced NSCLC (non-small cell lung cancer).
• In September 2022, Amgen has announced result in detail from Phase 3 CodeBreak 200 trial which has showed once daily oral LUMAKRAS/LUMYKRAS that has led to significantly higher objective response rate (ORR – key secondary endpoint) in patients with KRAS G12C-mutated NSCLC (non-small cell lung cancer) compared with intravenous chemotherapy, docetaxel.

• Novartis AG*
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• AstraZeneca
• Hoffman La Roche
• Eli Lilly and Company
• Pfizer Inc.
• Merck & Co.
• Amgen Inc.*
• Johnson & Johnson
• Teva Pharmaceuticals Industries Ltd.
• Bristol-Myers Squibb Company.

“*” marked represents similar segmentation in other categories in the respective section.

Research Objective and Assumption

• Research Objectives
• Assumptions
• Abbreviations

Market Preview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Type
  • Market Snippet, By Treatment
  • Market Snippet, By End-User
  • Market Snippet, By Region
• Opportunity Map Analysis

Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Market Trends
• Product Launch
• Merger and Acquisitions
• Impact Analysis
• PEST Analysis
• Porter’s Analysis

Market Segmentation, Type, Forecast Period up to 10 Years, (US$ Bn)

• Overview
  • Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Segment Trends
• Small cell lung cancer (SCLC)
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Non-small cell lung cancer (NSCLC)
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Segment Trends

Market Segmentation, Treatment, Forecast Period up to 10 Years, (US$ Bn)

• Overview
  • Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Segment Trends
• Chemotherapy
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Laser Therapy
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Radiotherapy
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Immunotherapy
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Surgery
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Others
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years

Market Segmentation, End-User, Forecast Period up to 10 Years, (US$ Bn)

• Overview
  • Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Segment Trends

• Hospitals
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Clinics
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Cancer Research Centre
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Laboratories
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Others
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years

Market Segmentation, By Region, Forecast Period up to 10 Years, (US$ Bn)

• Overview
  • Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Regional Trends
• North America
  • Market Size and Forecast (US$ Bn), By Type, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Treatment, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By End-User, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
    • U.S
    • Canada
• Asia Pacific
  • Market Size and Forecast (US$ Bn), By Type, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Treatment, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By End-User, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
    • India
    • Japan
    • South Korea
    • China
    • Rest of Asia Pacific
• Europe
  • Market Size and Forecast (US$ Bn), By Type, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Treatment, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By End-User, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
    • UK
    • Germany
    • France
    • Russia
    • Italy
    • Rest of Europe
• Latin America
  • Market Size and Forecast (US$ Bn), By Type, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Treatment, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By End-User, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
    • Brazil
    • Mexico
    • Rest of Latin America
• Middle East and Africa
  • Market Size and Forecast (US$ Bn), By Type, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Treatment, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By End-User, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
    • GCC
    • Israel
    • South Africa
    • Rest of Middle East and Africa

Competitive Landscape

• Heat Map Analysis
• Company Profiles

• Novartis AG*
• AstraZeneca
• Hoffman La Roche
• Eli Lilly and Company
• Pfizer Inc.
• Merck & Co.
• Amgen Inc.
• Johnson & Johnson
• Teva Pharmaceuticals Industries Ltd.
• Bristol-Myers Squibb Company.

The Last Word

• Future Impact
• About Us
• Contact